Summary High body weight is associated with increased production of oestrogens which may influence the clinical behaviour of breast cancer. We have examined the influence of body weight on the response to endocrine therapy, steroid hormone receptor content and survival in 227 women who either presented with or developed advanced cancer of the breast. One hundred and thirty-three (59%) patients presented with operable disease and 94 (41%) with locally advanced tumours. Two hundred (88%) were treated by tamoxifen and 27 (12%) by ovarian ablation.
Most epidemiological evidence suggests that high body weight and obesity are correlated with the incidence of breast cancer, particularly in postmenopausal women (Dewaard, 1982) . Furthermore, these factors are generally associated with a worse prognosis (Papatestas et al., 1986; Abe et al., 1976; Eberlein et al., 1985; Greenberg et al., 1985; Tartter et al., 1981; Newman et al., 1986; Boyd et al., 1981) , although one small study did not confirm this effect (Sohrabi et al., 1980) . Similarly in mice, obesity and a fat enriched diet increase the incidence and speed of onset of mammary tumours (Waxler et al., 1979) .
In postmenopausal women the major source of oestrogens is the conversion of androstenedione, derived from the adrenal gland, to oestrone in body fat by the aromatase system (Cloncope, 1971; MacDonald et al., 1969) . The strong correlation between the production of oestrone, the degree of this conversion and indices of obesity (e.g., weight, percentage of ideal weight and weight:height ratio) suggests that the excess production of steroid hormones within body fat which promotes the growth of mammary epithelial cells, may be the mechanism whereby there is an association between body weight and tumour incidence (Rizkallah et al., 1975; McDonald et al., 1978; Kirschner et al., 1982) . This is supported by the report of lower levels of sex hormone binding globulin in the obese which may lead to higher levels of free oestrogens (Kirschner et al., 1982) .
Our working hypothesis for this study was that the greater endogenous production of growth promoting steroids in women of above average weight might override the effects of endocrine treatment and lead to a lower response rate and reduced survival in this group. We have therefore studied a group of 227 patients who developed advanced, evaluable cancer of the breast, all of whom were treated either with tamoxifen, or by ovarian ablation. Table II .
Patients and methods

Patients
All were assessable for response by UICC criteria (Hayward et al., 1977) . Tumour oestrogen and progesterone receptors were analysed as previously described (Harland et al., 1983; Barnes et al., 1977) .
Statistical methods
Survival curves were calculated by the Kaplan-Meier method and compared by the log-rank test (Peto et al., 1977) . Body weight as a continuous variable and other factors of potential prognostic importance (recorded in Tables I and II) were included in a multivariate analysis using the Cox proportional hazards model (Cox, 1972) . The distribution of body weight in relation to several patient and tumour variables and response to treatment was investigated by one-way analysis of variance. Pairwise comparisons were made when a significant difference was found using Scheffe's Test. Body weight at the start of endocrine therapy was related to response, time to progression and survival from the start of therapy. Body weight at presentation was used for the other analyses.
Results
The median weight of the patients was 64kg. There was no significant difference in the survival of the whole group from the start of endocrine therapy, between patients who were above or below the median weight (P=0.95, Figure la ).
There was also no difference in the time to progression of G. WILLIAMS et al. (88) disease between the two groups (P = 0.29, Figure b) . Amongst those patients who presented with operable disease (n= 133), there were no significant differences in overall survival (P=0.42), relapse-free survival (P=0.69, Figure lc) , or survival from the start of endocrine therapy (P=0.85), between those patients who were above or below the median weight. Menopausal status did not affect these results. There was also no relationship between the time to progression and survival between the two groups when individual response categories (i.e., complete and partial response, no change and progressive disease) or individual receptor categories (i.e., ER+, ER-, PR+, PR-) were considered.
All the above analyses were repeated after dividing patients into three groups by weight (<60kg, 60-70kg and >70kg) and similar results were found. The distribution of body weight was unrelated to the age of the patient, menopausal status, histology of the tumour, axillary node status and the nature of the response to endocrine therapy (Table III) . There was however, a significant association between body weight and the stage of the tumour at presentation (P=0.002, Table III ).
There was no significant relationship between body weight and the ER status of the primary tumour and this held true when the first time of measurement was considered, i.e., either on presentation, or first relapse, or at the start of endocrine treatment (Table IV) Several studies have reported an association between high body weight and axillary lymph node involvement (Abe et al., 1976; Eberlein et al., 1985; Greenberg et al., 1985; De Waard et al., 1977) . In some of these there was also an association between high body weight and reduced disease free and overall survival (Abe et al., 1976; Eberlein et al., 1985; Greenberg et al., 1985) . Patients above the median weight are more likely to be obese and to have large breasts where small tumours are more difficult to detect than in small breasts and it is well described that the larger the tumour the more likely axillary nodes are to be involved. The reported reduced survival of obese patients may be due to relatively late presentation, however, in some studies the adverse effect of obesity persisted after adjustment for tumour size and axillary node status (Greenberg et al., 1985; Tartter et al., 1981; Boyd et al., 1981 However, in the group of patients with advanced disease in our study there was no relationship between body weight and the probability of response to endocrine therapy.
In the multivariate analysis for factors which affect survival from the start of endocrine therapy, response was of overriding importance. There was no association between body weight and the ER content of the tumour which is in agreement with one study (Eberlein et al., 1985) but not another in which a higher incidence of ER -ve tumours in heavier patients was reported (Papatestas et al., 1986) . For ER positive tumours, PR is significantly more likely to be present among heavier women, which is consistent with the fact that oestrogen may combine with its receptor to induce PR. There was a significant correlation between high body weight and PR positivity and the ER+PR+ combination, which confer a higher likelihood of response to endocrine therapy (Adami et al., 1984) . No 
